WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Psychedelics are being investigated as a treatment for depressive and anxiety disorders. Data on the interaction of selective serotonin reuptake inhibitors (SSRIs) with psychedelics are scarce. A first study in healthy participants showed that 2-week pre-administration of the SSRI escitalopram did not alter the acute pleasant subjective effects of the psychedelic psilocybin but reduced subjective “bad drug effect” and “anxiety” compared with placebo.